C4 Imaging LLC today announced that President and CEO, Andrew Bright, will present at the Medtech Showcase 2017 (A Biotech Showcase™), taking place at the Parc 55 Hotel in San Francisco, January 10 – 11. He is scheduled to speak on Tuesday, January 10 at 9.30am PST and will review current and future applications of C4 Imaging’s unique MRI contrast technology. Also attending the Medtech showcase will be Dr. Steven Frank, Chairman and Founder of C4 imaging. Dr.Frank is a Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is Medical Director at the Proton Therapy Center and Director of Advanced Technologies for the Department of Radiation Oncology.
C4 Imaging LLC today announced the presentation of a clinical study describing the use of Magnetic Resonance Imaging (MRI) in improving the quality of prostate cancer treatment. The data on 47 patients treated with prostate brachytherapy was presented at The World Congress of Brachytherapy meeting held in San Francisco, June 27 – 29, 2016.
C4 Imaging LLC announced that it has been recognized as one of the Rice Alliance 10 Most Promising Life Science Companies at the 2016 Texas Life Science Forum hosted by the Rice Alliance for Technology and Entrepreneurship and BioHouston and Texas Healthcare and BioScience Institute at the BioScience Research Collaborative in Houston, May 26. The companies were chosen by industry experts and investors. More than 50 startup companies presented their business plan presentations at the forum. An additional six Nasdaq-listed life science companies provided status updates.
C4 Imaging LLC has chosen leading specialty chemicals company Evonik Corporation and its Resource Efficiency segment’s VESTAKEEP® PEEK polymer technology in the design of Sirius™, a recently developed Positive-Signal Magnetic Resonance Imaging (MRI) Marker used during the treatment of prostate cancer.
C4 Imaging LLC today announced it has been awarded a $1.32 Million Phase II Small Business Innovation Research (“SBIR”) grant from the National Cancer Institute of the National Institutes of Health (“NIH”). Entitled “Multi-Modality MRI/CT Markers for Improved Assessment of Prostate Cancer”, the Phase II SBIR award will help fund the development of an enhanced multi-modality imaging marker based on C4 Imaging’s commercially available Sirius™ MRI Marker.
“This first implant is a significant milestone,” said Andrew Bright, President and CEO of C4 Imaging. “MR imaging of the implanted Sirius™ MRI Markers was successful and the clinical team were able to localize the implanted seeds.” He added, “We were delighted to partner with IsoRay™ Medical for this first implant.
C4 Imaging will partner with Florida-based AnazaoHealth Corporation, a leading provider of patient-specific prescription-loaded brachytherapy products for treating prostate cancer. Under the agreement AnazaoHealth will load the Sirius™ MRI Marker alongside seeds into brachytherapy strands and needles according a physician prescription tailored to each individual patient.
C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel positive-signal, MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance (MR) imaging procedure.